🤖 This initiative aims to produce 100 million vaccine doses annually by 2040, ensuring self-sufficiency.
🏭 The collaboration with DNA Script and Quantoom Biosciences will establish an advanced production facility in Egypt.
🔬 AI will enhance various stages, from antigen selection to delivery system modeling.
💊 The goal is to meet local and continental health needs efficiently.
Introduction:
The integration of artificial intelligence (AI) and automation in vaccine production is becoming a significant focus in global health efforts. A notable initiative is spearheaded by Egyptian firm Eva Pharma, in collaboration with DNA Script and Quantoom Biosciences, aiming to establish a self-sufficient RNA vaccine manufacturing system in Africa by 2040. This ambition is part of a larger African Vaccine Manufacturing Accelerator (AVMA) program directed by the Africa CDC.
- Eva Pharma is establishing an end-to-end mRNA production platform to manufacture up to 100 million RNA vaccine doses annually.
- The collaboration involves the integration of DNA Script’s synthesis technologies and Quantoom’s mRNA synthesis systems.
- Automation will play a central role, enabling a fully automated manufacturing line through process analytical technologies.
- AI will facilitate processes including antigen selection, protein engineering, and modeling delivery systems for vaccines.
- This manufacturing effort is part of a broader initiative to ensure Africa produces 60% of its vaccines by 2040, enhancing local capacity and reducing dependence on external sources.
Conclusion:
The collaboration between Eva Pharma, DNA Script, and Quantoom Biosciences represents a transformative approach to vaccine manufacturing in Africa, leveraging AI and automation to enhance production efficiency. The initiative is pivotal for achieving regional vaccine self-sufficiency and responds to the urgent need for local production capabilities seen during the COVID-19 pandemic. As this project progresses, it may significantly influence the landscape of global vaccine distribution and accessibility in the coming years.
